What is Gilteritinib? A Complete Guide for AML Patients

Release date: 2026-03-11 16:27:24     Recommended: 138

Indications and Efficacy

The main component of Gilteritinib Fumarate Tablets is gilteritinib fumarate, which is an anti-tumor medication.

This medication should be used under the guidance and supervision of a physician experienced in anti-tumor therapy. Peripheral blood or bone marrow FLT3 mutation testing must be performed before initiating treatment.

This product is not recommended for use during pregnancy or breastfeeding; male patients requiring treatment should use effective contraceptive measures.

Gilteritinib Fumarate Tablets are an anti-tumor medication whose main component is gilteritinib fumarate. It is primarily used to treat patients with a specific type of leukemia — those who meet two criteria: first, they have relapsed or refractory acute myeloid leukemia (AML), and second, the presence of an FLT3 mutation has been confirmed by a reliable testing method.

What diseases can Gilteritinib Fumarate Tablets treat?

Lucius Pharmaceuticals Gilteritinib Fumarate belongs to the second generation of tyrosine kinase receptor inhibitors (tyrosine kinases are important substances that regulate cell growth; when abnormally active, they may promote cancer cell proliferation). It precisely inhibits FLT3 receptor signaling, including types such as FLT3-ITD mutations and tyrosine kinase domain mutations (e.g., D835Y). In simple terms, this medication works by blocking abnormal signaling, inhibiting the proliferation of leukemia cells, and promoting the gradual death of these abnormal cells, thereby controlling disease progression.

What symptoms can Gilteritinib Fumarate Tablets alleviate?

This medication is indicated for the following two patient groups:

Adult patients with acute myeloid leukemia whose disease has relapsed after standard treatment.

Adult patients with acute myeloid leukemia who do not respond adequately to existing treatment regimens (i.e., refractory disease).

It is important to note that patients must have a confirmed FLT3 gene mutation (FLT3 is a key gene affecting blood cell development; mutations may lead to worsening leukemia) through professional hospital testing to be eligible for treatment.